U.S. Disinfecting Cap Market Size to Exceed USD 1,354.8 Mn by 2032

The U.S. Disinfecting Cap Market, estimated at USD 656.7 Mn in 2025, is expected to exhibit a CAGR of 10.9% and reach USD 1,354.8 Mn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Increasing usage of disinfecting caps to reduce central line-associated bloodstream infections (CLABSIs) is expected to drive the U.S. disinfecting cap market growth over the forecast period. For instance, in September 2025, the data published by American Journal of Infection Control, according to a literature search by using MedLine, EMBASE, Cochrane library, and CINAHL, to determine the efficacy and safety of disinfecting caps to reduce the risk of CLABSIs. Hence, it was stated that patients using disinfectant caps had lower risk of Line-associated Bloodstream Infections (CLABSIs).

U.S. Disinfecting Cap Market – Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and consequent lockdowns in various countries worldwide impacted the financial status of businesses across all sectors, including the private healthcare sector. COVID-19 pandemic impacted the entire supply chain of the healthcare industry due to strict lockdowns in several regions. The private healthcare is one such sector that has been significantly impacted by the COVID-19 pandemic.

Many patients with COVID-19 have severe respiratory infection that requires hospitalization and mechanical ventilation. The governments of various countries are focusing on promoting initiatives to fight against the COVID-19 pandemic, and to stop the spread of the coronavirus infection by implementing various regulatory measures in the countries. Furthermore, , the governments of various countries have collaborated with universities globally to find novel treatment options for curing COVID-19 and its related complications. For instance, according to an article published by Journal of Laparoendoscopic and Advanced Surgical Techniques, in April 2025, an observational study was conducted among the total population in U.S. It was estimated that the demand for surgeries had reduced to hospital-acquired infections. Hence, it hamper the market growth as it reduced the demand for disinfecting caps.

Browse 10 Market Data Tables and 15 Figures spread through 150 Pages and in-depth TOC on the “U.S. Disinfecting Cap Market”- Forecast to 2032, U.S. Disinfecting Cap Market, By Application (Central Venous Line, Peripheral IV Catheters, and Others (Blood Collection, etc.)), By Type (Single Cap System and Double Cap System), and By End User (Hospital and Clinics, Ambulatory Surgical Centers, and Others (Outpatient Surgical Centers, etc.))

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-disinfecting-cap-market-3630

Key Takeaways of the U.S. Disinfecting Cap Market:

• The U.S. disinfecting cap market is expected to exhibit a CAGR of 10.9% over the forecast period due to increasing prevalence of infections associated with peripheral intravenous catheters. For instance, in September 2025, according to the data published by t National Center for Biotechnology Information, a survey was conducted at tertiary care university hospital in the U.S. Thus, it was estimated that approximately 47% of patients were associated with peripheral intravenous catheter infection.
• Among application, the central venous line segment is estimated to hold a dominant position in the U.S. disinfecting cap market over the forecast perioddue to increasing prevalence of central venous line infections. For instance, in September 2025, according to the data published by Science Direct, cancer patients frequently require central venous catheters for therapy and parenteral nutrition, and are at a high risk of central venous Catheter–related Infections (CRIs). Products such as sterile gowns and disinfecting caps are used to decrease the risk of CRIs. As CRIs are often preceded by hub colonization, disinfectant caps are used to reduce the incidence of CRIs in cancer patients.
• The major players operating in the U.S. disinfecting cap market include ICU Medical, BD, 3M, Merit Medical Systems, Omnia Health, B. Braun SE, Agilent Technologies Inc., Biocrates Lifescience AG, Bio-Rad Laboratories Inc., Pursuit Vascular Inc., and JCM MED